# Niraparib in High-grade Endometrial Cancer Trial

> **NCT05289648** · EARLY_PHASE1 · WITHDRAWN · sponsor: **Sir Mortimer B. Davis - Jewish General Hospital**

## Conditions studied

- Endometrial Cancer
- Serous Adenocarcinoma
- Uterine Neoplasm

## Interventions

- **DRUG:** Niraparib oral capsule

## Key facts

- **NCT ID:** NCT05289648
- **Lead sponsor:** Sir Mortimer B. Davis - Jewish General Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-05-01
- **Primary completion:** 2025-10-31
- **Final completion:** 2026-01-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Unable to obtain funding
- **Last updated:** 2024-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05289648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05289648, "Niraparib in High-grade Endometrial Cancer Trial". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05289648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*